Adenocarcinoma of Lung Clinical Trials

8 recruiting

Adenocarcinoma of Lung Trials at a Glance

8 actively recruiting trials for adenocarcinoma of lung are listed on ClinicalTrialsFinder across 6 cities in 5 countries. The largest study group is Phase 2 with 2 trials, with the heaviest enrollment activity in Beverly Hills, Brainerd, and Chuo-ku. Lead sponsors running adenocarcinoma of lung studies include Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Geneplus-Beijing Co. Ltd., and Azienda USL Reggio Emilia - IRCCS.

Browse adenocarcinoma of lung trials by phase

Treatments under study

About Adenocarcinoma of Lung Clinical Trials

Looking for clinical trials for Adenocarcinoma of Lung? There are currently 8 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Adenocarcinoma of Lung trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Adenocarcinoma of Lung clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 18 of 8 trials

Recruiting
Phase 1

A Study of Tumor-Treating Fields (TTFields) in People With Lung Adenocarcinoma

Adenocarcinoma of Lung
Memorial Sloan Kettering Cancer Center25 enrolled7 locationsNCT05764954
Recruiting

Using Biomarkers for Diagnosis, Risk Stratification of Post -Treatment Recurrence and Long-Term Surveillance of Lung Cancer

Lung; NodeAdenocarcinoma of Lung
H. Lee Moffitt Cancer Center and Research Institute250 enrolled1 locationNCT05665504
Recruiting
Phase 2

A Study of LP-300 With Carboplatin and Pemetrexed in Never Smokers With Advanced Lung Adenocarcinoma

Adenocarcinoma of Lung
Lantern Pharma Inc.90 enrolled16 locationsNCT05456256
Recruiting
Phase 2

RMT in Combination With Durvalumab + Chemo in Untreated Adenocarcinoma NSCLC. A Randomized Double Blind Phase II Trial

Lung CancerAdenocarcinoma of Lung
Masonic Cancer Center, University of Minnesota82 enrolled10 locationsNCT04105270
Recruiting
Not Applicable

Bioimpedance Analysis in Perioperative Assessment in Thoracic Surgery

Lung ResectionAdenocarcinoma of Lung
Azienda USL Reggio Emilia - IRCCS1,000 enrolled1 locationNCT06796816
Recruiting

Therapeutic ResistAnce and Clonal Evolution Assessed With Liquid Biopsy in ICIs Treated NSCLC Patients

Lung NeoplasmsLung Cancer, Nonsmall CellAdenocarcinoma of Lung+1 more
Geneplus-Beijing Co. Ltd.250 enrolled1 locationNCT04566432
Recruiting

Differentiating the Invasiveness of Lung Adenocarcinoma by Dual Energy CT Parameter

Adenocarcinoma of Lung
Tang-Du Hospital2,000 enrolled1 locationNCT06441357
Recruiting

APOLLO 11, Consortium of Italian Centers Involved in Treatment of Patients With Lung Cancer Treated With Innovative Therapies: Real World Data and Translational Reaserch

Lung CancerCancerNSCLC+2 more
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano1,200 enrolled1 locationNCT05550961